---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-021266"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2022-05-25T23:59:59+00:00"
generated_at: "2026-06-25T07:26:01.018086+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FDA approves Tyvaso DPI using MannKind's Technosphere platform; availability June 2022

## Summary
- Tyvaso DPI is second FDA-approved product using MannKind's Technosphere inhalation platform; first dry powder inhaled treatment for PAH and PH-ILD.
- Manufacturing of Tyvaso DPI underway at MannKind's Connecticut facility; product availability expected in June 2022.
- Commercial supply agreement with United Therapeutics runs through 2031; initially signed in August 2021.
- Tyvaso DPI uses dry powder formulation and Dreamboat inhaler technology from Afrezza; convenient alternative to liquid nebulization.

## SEC filing metadata
- accession: 0001564590-22-021266
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2022-05-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000156459022021266/0001564590-22-021266-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000156459022021266/mnkd-8k_20220524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-021266
- JSON: https://secwatch.observer/filing/0001564590-22-021266.json
- Plain text: https://secwatch.observer/filing/0001564590-22-021266.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.